Approval received for NTI164 Phase 3 Clinical Study in ASD

• Human Research Ethics Committee approval secured to commence Neurotech’s Beyond Harmony Phase 3 clinical study of NTI164 in ASD Levels 2 and 3. • Study is designed to support regulatory submissions for NTI164 in Australia (TGA) and the United States (FDA). • The Phase 3 design is informed by Neurotech’s prior ASD studies showing statistically significant, clinically meaningful improvements acros